[HTML][HTML] Optimization of RGD-modified nano-liposomes encapsulating eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard… - Iranian Journal of …, 2016 - ncbi.nlm.nih.gov
Background Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
[HTML][HTML] Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard… - Iranian Journal of …, 2016 - ijbiotech.com
Background: Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
[PDF][PDF] Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard, F Dorkoosh - Iran J Biotech, 2016 - sid.ir
1. Background Atherosclerosis is among the major causes of the cardiovascular disease,
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati… - Iranian journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide.
H Bardania, SA Shojaosadati, F Kobarfard… - Iranian Journal of …, 2016 - europepmc.org
Background Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
[PDF][PDF] Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard… - Iran J Biotech, 2016 - academia.edu
1. Background Atherosclerosis is among the major causes of the cardiovascular disease,
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
[PDF][PDF] Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard… - Iran J …, 2016 - researchgate.net
1. Background Atherosclerosis is among the major causes of the cardiovascular disease,
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
Optimization of RGD-modified nano-liposomes encapsulating eptifibatide
B Hassan, S Seyed, K Farzad, D Farid - 2016 - pesquisa.bvsalud.org
Background: Eptifibatide [Integrilin] is an intravenous [IV] peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
[HTML][HTML] Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard… - Iranian Journal of …, 2016 - ijbiotech.com
Background: Eptifibatide (Integrilin) is an intravenous (IV) peptide drug that selectively
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
inhibits ligand binding to the platelet GP IIb/IIIa receptor. It is an efficient peptide drug …
[PDF][PDF] Optimization of RGD-modified Nano-liposomes Encapsulating Eptifibatide
H Bardania, SA Shojaosadati, F Kobarfard… - Iran J …, 2016 - researchgate.net
1. Background Atherosclerosis is among the major causes of the cardiovascular disease,
which results from platelet aggregation, plaque formation, ending to the occlusion of the …
which results from platelet aggregation, plaque formation, ending to the occlusion of the …